en · de · es · fr · pt
tesamorelin-notes.peptides8425.com › Data › Tesamorelin Identity And Structure — Evidence Review

Tesamorelin Identity And Structure — Evidence Review

By Editorial Desk · published 2025-08-19 · last reviewed 2025-10-11 · Data

The short version of TH9507 fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2025-10-11. Anything still debated is marked as such rather than presented as settled.

Tesamorelin Identity And Structure

Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.

The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.

Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.

特沙莫瑞林分析与储存要点

稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定,复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集,这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。

质量控制项目一般包括外观、身份、纯度、含量、有关物质、水分和微生物限度。身份确认可通过肽图谱、氨基酸分析和质谱完成,纯度则用面积归一化法计算。研究级材料与药品级材料的要求不同,前者常缺少完整药典验证。不同批次间杂质谱是否影响活性,仍是一个需要具体数据回答的问题。

特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质,质谱则提供精确质量以确认身份。对于复杂基质中的定量,常采用液相色谱-串联质谱,并配合固相萃取或蛋白沉淀。生物样品中的肽易降解,因此采集和处理条件会影响结果。

Tesamorelin at a glance

PropertyValueNotes
Chemical classSynthetic peptideGHRH analog family
Residue count44 amino acidsMatches human GHRH(1-44) backbone
N-terminal grouptrans-3-hexenoylMain structural difference from native hormone
AppearanceWhite to off-white powderLyophilized solid form
Solubility classFreely soluble in waterPeptide character; less soluble in organic solvents

Identity and Development Background

Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.

Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.

Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.

Related pages on this site

Analytical Methods and Storage Handling

Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.

Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.

Supporting material

(2026) study the anatomy of ulna and femur or Sahelanthropus tchadensis, interpreted as indicative of presence of adaptations to bipedalism in spite of similarities in size and geometric morphometric shape to bones of chimpanzees. De Jager et al. (2026) study the frequency, position, and variability of cortical sulcal imprints in endocasts of extant chimpanzees and bonobos, providing a comparative resource for the studies of the brain evolution based on hominin fossils. Dunbar (2026) reevaluates data from the study of Deaner & Nunn (1999), finds evidence of changes in brain size following increases in body size in the evolution of primates but in a more complicated way that suggested by the original brain lag hypothesis, with an increase in body size followed by a progressively greater increase in brain size, and finds evidence of such evolution of brain and body size in hominins.

Gorlin's sign is a medical term that indicates the ability in humans to touch the tip of the nose with the tongue. Approximately ten percent of the general population can perform this act, but fifty percent of people with Ehlers–Danlos syndrome (an inherited connective tissue disorder) have the ability. The sign is named after pathologist Robert J. Gorlin, who described it in twentieth century medical literature. Gorlin's sign should not be confused with Gorlin syndrome, a serious inherited medical condition also named after the same pathologist.

== Treatment == There is no known cure for Becker muscular dystrophy yet. Treatment is aimed at control of symptoms to maximize the quality of life which can be measured by specific questionnaires. Activity is encouraged and can be considered vital for long-term survivability for these patients. Inactivity (such as bed rest) or sitting down for too long can worsen the muscle disease. Physical therapy may be helpful to maintain muscle strength. Orthopedic appliances such as braces and wheelchairs may improve mobility and self-care. Immunosuppressant steroids have been known to help slow the progression of Becker muscular dystrophy. The drug prednisone contributes to increased production of the protein utrophin which closely resembles dystrophin, the protein that is defective in BMD. The cardiac problems that occur with EDMD and myotonic muscular dystrophy may require a pacemaker. Other cardiomyopathies seen in Becker muscular dystrophy can also be treated with ACE inhibitors, cardiac transplant, and other personalized treatments. The investigational drug Debio-025 is a known inhibitor of the protein cyclophilin D, which regulates the swelling of mitochondria in response to cellular injury. Researchers decided to test the drug in mice engineered to carry MD after earlier laboratory tests showed deleting a gene that encodes cyclophilin D reduced swelling and reversed or prevented the disease's muscle-damaging characteristics. According to a review by Bushby, et al.

== Work == Development of dedicated machinery for insulin extraction and purification at the Zoophysiology Laboratory workshop. Design and implementation of early insulin delivery technologies (the "Novo Syringe" for self-injection). Co-development of Insulin Novo, marketed by Novo Terapeutisk in the mid-1920s.

Sources: en.wikipedia.org

Notes from published material

=== Cancer === Cilengitide, a cyclic pentapeptide (RGDfV), is an investigational drug intended to block the growth of new blood vessels in tumors by interfering with the activation of integrin αVβ3. This integrin is upregulated in tumor and activated endothelial cells. This and other anti-angiogenic therapies depend on cutting off the blood supply to the tumor micro-environment, leading to hypoxia and necrosis. Cilengitide has been evaluated for the treatment of glioblastoma, but, as is the case for other anti-angiogenic therapies, has not been shown to alter progression or improve survival either alone or in combination with standard treatments.

However, despite having a historically developed non-fixed mystical and developing canon, Bektashism officially upholds the Four Holy Books - Torah, Psalms, Gospel and Quran - as central book of the faith and insist they cannot be removed, they are not corrupted in inner meaning even if in zahir they may contradict, and all contain important esoteric meanings beyond their literal textual understanding so there is no rejection of the scriptures instead there is centralisation of scriptures. Bektashis made effort to translate Quran verses into local languages, since scripture is not just in on paper but actions these translations are not direct but in poetic form to show esoteric meaning behind the verses.

Nutty Professor II: The Klumps is a 2000 American science fiction comedy film directed by Peter Segal and starring Eddie Murphy and Janet Jackson. It is the sequel to the 1996 film The Nutty Professor. In contrast to the previous film, subplots centered on the parents of protagonist Sherman Klump occupy a substantial part of the film. Nutty Professor II: The Klumps was released by Universal Pictures on July 28, 2000. Unlike its predecessor, the film received generally negative reviews and grossed $166.3 million.

== Uses == A precursor for mercaptan is 3-mercapto-3-methylbutanol (MMB). MMB is a chemical which gives a strong odor to cat urine. This smell is likely used for communicating amongst cats as well as scaring away predators and rivals. That is, the smell can mark their territory amongst other male cats and attract a female mate.

Alcohol interacts with cocaine in vivo to produce cocaethylene, another psychoactive substance which may be substantially more cardiotoxic than either cocaine or alcohol by themselves. In 2024, a systematic review of human studies concluded that, despite some inconsistencies in the findings, the co-use of cocaine and alcohol poses a significantly greater risk of cardiovascular fatalities compared to cocaine use alone. This elevated risk is largely attributed to the formation of cocaethylene, a unique and toxic metabolite produced only when both substances are consumed together. Cocaethylene is associated with an 18- to 25-fold increased risk of sudden death, as well as a higher incidence of myocardial injury and cardiac arrest, underscoring the serious health risks of simultaneous cocaine and alcohol use.

Sources: en.wikipedia.org

Background from the literature

The life science business unit specializes in genomics, and involves the development of oligonucleotides, DNA polymerases, Real-time qPCR Probes, assay services, and proteomics. The proteomics operations are primarily concerned with custom peptides and antibodies, assay kits and Proprietary Dyes & Quenchers. The in vitro diagnostics business unit provides technical and project support for contract manufacturing of good manufacturing practice (GMP) Oligonucleotides and Taq DNA polymerases for use in Molecular Diagnostic applications. Manufacturing processes take place in clean rooms. The GMP BioManufacturing BU, is a full-service Contract Manufacturing Organization (CMO) and offers significant know-how in process development, technology transfer, formulation, scale-up and manufacturing of GMP proteins, protein conjugates, plasmids and bacterial vaccines for pre-clinical, clinical and commercial uses, all according to U.S. Food and Drug Administration (FDA) and EMA requirements.

=== Detection in body fluids === Caffeine can be quantified in blood, plasma, or serum to monitor therapy in neonates, confirm a diagnosis of poisoning, or facilitate a medicolegal death investigation. Plasma caffeine levels are usually in the range of 2–10 mg/L in coffee drinkers, 12–36 mg/L in neonates receiving treatment for apnea, and 40–400 mg/L in victims of acute overdosage. Urinary caffeine concentration is frequently measured in competitive sports programs, for which a level in excess of 15 mg/L is usually considered to represent abuse.

=== Long-term worsening of psychiatric symptoms === While benzodiazepines may have short-term benefits for anxiety, sleep, and agitation in some patients, long-term (i.e., greater than 2–4 weeks) use can result in a worsening of the very symptoms the medications are meant to treat. Potential explanations include exacerbating cognitive problems that are already common in anxiety disorders, causing or worsening depression and suicidality, disrupting sleep architecture by inhibiting deep stage sleep, withdrawal symptoms or rebound symptoms in between doses mimicking or exacerbating underlying anxiety or sleep disorders, inhibiting the benefits of psychotherapy by inhibiting memory consolidation and reducing fear extinction, and reducing coping with trauma/stress and increasing vulnerability to future stress. The latter two explanations may be why benzodiazepines are ineffective and/or potentially harmful in PTSD and phobias. Anxiety, insomnia and irritability may be temporarily exacerbated during withdrawal, but psychiatric symptoms after discontinuation are usually less than while taking benzodiazepines. Functioning significantly improves within one year of discontinuation.

== History == Results of a Phase I clinical trial were reported in 2016. In December 2019, enfortumab vedotin was approved in the United States for the treatment of adult patients with locally advanced or metastatic urothelial cancer who had previously received a programmed cell death receptor-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy. The approval was based on the results of a clinical trial of 125 such patients. The overall response rate, reflecting the percentage of patients who had a certain amount of tumor shrinkage, was 44%; specifically, 12% had a complete response and 32% a partial response. The median duration of response was 7.6 months. The U.S. Food and Drug Administration (FDA) granted the application for enfortumab vedotin accelerated approval, priority review designation, and breakthrough therapy designation. The FDA granted the approval of Padcev to Astellas Pharma US Inc. In July 2021, the FDA approved enfortumab vedotin for adults with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy, or who are ineligible for cisplatin-containing chemotherapy and have previously received therapy.

Sources: en.wikipedia.org

Frequently asked questions

Is tesamorelin the same as growth hormone?

No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.

What does the trans-3-hexenoyl group do?

It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.

How long is the peptide chain?

The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.

哪些分析方法常用于确认特沙莫瑞林?

反相高效液相色谱用于分离和纯度评估,质谱用于分子量确认。肽图谱或串联质谱可进一步验证序列。具体方法需根据样品基质和监管要求选择。

Network